
    
      The present study is designed to demonstrate pharmacokinetic and pharmacodynamic equivalence
      of Biocon Insulin 70/30 with HumulinÂ® 70/30 in healthy subjects The treatment consists of one
      single dose of the test or reference product, administered during each of the two study
      periods, separated by 5-7 days between dosing. The planned trial duration for each subject is
      about 12 to 36 days.

      Eligible subjects will undergo two 24-hour euglycaemic clamp examinations, one after
      administration of the test product and one after administration of the reference product in
      random order.
    
  